Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests could reveal who benefits from immunotherapy

NCT ID NCT05091190

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at how well immunotherapy works in people with advanced lung or head and neck cancers. Researchers will take blood samples before and after treatment to measure how the body clears the drug and how tumor cells in the blood change. The goal is to find markers that predict who will respond best to immunotherapy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
immunotherapy
What this could lead to
If successful, this could help doctors predict which patients will benefit from immunotherapy, leading to more personalized cancer treatment.
What could go wrong
This is an observational study with only 75 participants, so results may not apply to all patients. It measures biomarkers, not direct treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

75 people

The number who actually took part.

Started

Oct 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Lung cancer (n= 30): * Adult patients * Patients who gave its written informed consent to participate to the study * Weight at inclusion ≥ 48 kg * NSCLC histology only * Stage IV according to 8th TNM classification * Planned to be treated with immunotherapy (+/- chemotherapy) as a first line treatment in metastatic setting * PD-L1 status on primary tumor available at the inclusion * Patients affiliated to a social insurance regime Head and neck cancer (n= 30): * Adult patients * Patients who gave its written informed consent to participate to the study * Weight at inclusion ≥ 48 kg * Recurrent or metastatic epidermoid carcinomas from oral cavity, oropharynx, hypopharynx, larynx (except nasopharynx) * Stage IV according to 8th TNM classification * Planned to be treated with immunotherapy (+/- chemotherapy) * PD-L1 status on primary tumor available at the inclusion * Patients affiliated to a social insurance regime Exclusion Criteria: * History of previous cancers, except for adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, treated and with no evidence of disease for ≥ 5 years * Patients under tutorship or guardianship * Pregnant or breast feeding women * Patients under psychiatric care Exclusion Criteria specific pour head and neck cohort: \- Patients already treated with immunotherapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic head and neck cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic head and neck cancer Metastatic NSCLC

Contacts and locations

Locations

  • Croix Rousse Hospital

    Lyon, France

  • Lyon Sud Hospital

    Pierre-Bénite, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.